Back to Search
RUTH O'REGAN, MD
MD
Medical Oncology Physician
NPI: 1215981238IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
308369(NY)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
308369(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1988
Research & Publications (20)
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
PMID 19636556·Cancer Chemother Pharmacol·2010
8-other
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
PMID 18324472·Breast Cancer Res Treat·2009
8-other
Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer.
PMID 19466698·Cancer·2009
8-other
Endocrine therapy for the treatment of postmenopausal women with breast cancer.
PMID 19192957·Expert Rev Anticancer Ther·2009
6-review
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.
PMID 18256926·Breast Cancer Res Treat·2009
8-other
Inorganic nanoparticles for predictive oncology of breast cancer.
PMID 19093898·Nanomedicine (Lond)·2009
7-preclinical
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.
PMID 18381457·Cancer Res·2008
8-other
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
PMID 19047149·Cancer Res·2008
8-other
Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging.
PMID 18570415·J Am Chem Soc·2008
7-preclinical
Targeted glycoproteomic identification of biomarkers for human breast carcinoma.
PMID 18271524·J Proteome Res·2008
8-other
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.
PMID 17952740·Cancer Invest·2007
3-trial
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry.
PMID 17546006·Nat Protoc·2007
8-other
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells.
PMID 17035597·Mol Pharmacol·2007
8-other
Selection of optimal adjuvant endocrine therapy for early-stage breast cancer.
PMID 16455026·Curr Treat Options Oncol·2006
6-review
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
PMID 16609042·Clin Cancer Res·2006
4-observational
Emerging use of nanoparticles in diagnosis and treatment of breast cancer.
PMID 16887483·Lancet Oncol·2006
6-review
Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation.
PMID 17163713·Nano Lett·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 601 ELMWOOD AVE
ROCHESTER, NY 14642 - Phone
- (585) 275-7938
Quick Facts
- NPI
- 1215981238
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile